The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1385
Clobazam (Onfi) for Lennox-Gastaut Syndrome
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Clobazam (Onfi – Lundbeck), an oral benzodiazepine, has been approved by the FDA for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients ≥2 years old. It has been available in Canada (Frisium) and other countries for years for treatment of anxiety and many types of epilepsy.

LENNOX-GASTAUT SYNDROME — LGS is a severe form of childhood epilepsy characterized by multiple types of seizures, developmental delays and impaired intellectual function. Most LGS patients require combinations of antiepileptic drugs to control their seizures. Drop attacks (atonic, tonic or myoclonic seizures resulting in sudden falls) occur in about half of patients with LGS. Most pediatric neurologists consider valproic acid (Depakene, and others) the first-line treatment, but only topiramate (Topamax, and others), lamotrigine (Lamictal, and others), ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Clobazam (Onfi) for Lennox-Gastaut Syndrome
Article code: 1385b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian